{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:10:39Z","timestamp":1792113039621,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s40265-019-01175-0","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T01:02:39Z","timestamp":1564189359000},"page":"1467-1475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":208,"title":["Polatuzumab Vedotin: First Global Approval"],"prefix":"10.1007","volume":"79","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,27]]},"reference":[{"key":"1175_CR1","unstructured":"ADC Review. What are antibody-drug conjugates (ADCs)? J Antibody Drug Conjugates. 2019. \n                    https:\/\/www.adcreview.com\/the-review\/antibody-drug-conjugates\/what-are-antibody-drug-conjugates\/\n                    \n                  . Accessed 28 Jun 2019."},{"key":"1175_CR2","unstructured":"The Human Protein Atlas. CD79B. 2019. \n                    https:\/\/www.proteinatlas.org\/ENSG00000007312-CD79B\/pathology\n                    \n                  . Accessed 28 June 2019."},{"key":"1175_CR3","unstructured":"Genentech Inc. Polivy\u2122 (Polatuzumab vedotin-piiq) for injection, for intravenous use: US Prescribing Information. 2019. \n                    https:\/\/www.fda.gov\n                    \n                  . Accessed 28 June 2019."},{"key":"1175_CR4","unstructured":"U.S. Food and Drug Administration. FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma. 2019. \n                    https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma\n                    \n                  . Accessed 28 Jun 2019."},{"key":"1175_CR5","unstructured":"Seattle Genetics Inc. Seattle Genetics announces antibody-drug conjugate agreement with Genentech [media release]. 22 Apr 2002. \n                    http:\/\/www.seattlegenetics.com\n                    \n                  ."},{"key":"1175_CR6","unstructured":"Seattle Genetics, Inc. Seattle Genetics establishes preferred antibody-drug conjugate manufacturing relationship with Albany Molecular Research, Inc [media release]. 13 Jul 2004. \n                    http:\/\/www.seattlegenetics.com\/\n                    \n                  ."},{"key":"1175_CR7","unstructured":"Seattle Genetics. Seattle Genetics receives additional $10 million from Genentech under antibody-drug conjugate collaboration [media release]. 19 Dec 2003. \n                    http:\/\/www.seattlegenetics.com\n                    \n                  ."},{"key":"1175_CR8","unstructured":"Seattle Genetics, Inc. Seattle Genetics and Genentech expand antibody-drug conjugate collaboration [media release]. 9 Nov 2004. \n                    http:\/\/www.seattlegenetics.com\n                    \n                  ."},{"key":"1175_CR9","unstructured":"Seattle Genetics, Inc. Seattle Genetics announces extension of antibody-drug conjugate collaboration with Genentech [media release]. 28 Mar 2007. \n                    http:\/\/www.seattlegenetics.com\n                    \n                  ."},{"key":"1175_CR10","unstructured":"Seattle Genetics, Inc. Seattle Genetics to receive $9.5 million payment from Genentech to extend antibody-drug conjugate collaboration [media release]. 20 Apr 2010. \n                    http:\/\/www.seattlegenetics.com\n                    \n                  ."},{"key":"1175_CR11","unstructured":"Seattle Genetics, Inc. Seattle Genetics expands antibody-drug conjugate collaboration with Genentech [media release]. 3 Aug 2010. \n                    http:\/\/www.seattlegenetics.com\n                    \n                  ."},{"issue":"7","key":"1175_CR12","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/leu.2015.48","volume":"29","author":"M Pfeifer","year":"2015","unstructured":"Pfeifer M, Zheng B, Erdmann T, et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia. 2015;29(7):1578\u201386.","journal-title":"Leukemia"},{"key":"1175_CR13","doi-asserted-by":"publisher","unstructured":"Tiwari AA, Ayello J, Van De Ven C, et al. Antibody drug conjugates (anti-CD79b-vc-MMAE, polatuzumab vedotin) exhibit enhanced cell death targeted to CD79b\u2009+\u2009Burkitt lymphoma (BL) and primary mediastinal large B-cell lymphoma (PMBL) [abstract no. 579]. Cancer Res. 2016;76(14 Suppl). \n                    https:\/\/doi.org\/10.1158\/1538-7445.AM2016-579\n                    \n                  .","DOI":"10.1158\/1538-7445.AM2016-579"},{"key":"1175_CR14","doi-asserted-by":"publisher","unstructured":"Tiwari AA, Edani D, Azmy C, et al. Enhanced in vitro\/in vivo cytotoxicity against Burkitt lymphoma\/primary mediastinal large B cell lymphoma by polatuzumab vedotin (hu-anti-CD79b-vc-MMAE, PV) alone or in combination with obinutuzumab [abstract no. 1788]. Cancer Res. 2018;78(13 Suppl). \n                    https:\/\/doi.org\/10.1158\/1538-7445.AM2018-1788\n                    \n                  .","DOI":"10.1158\/1538-7445.AM2018-1788"},{"key":"1175_CR15","doi-asserted-by":"publisher","unstructured":"Amin DN, Oeh J, Zindal A, et al. Anti-tubulin antibody drug conjugates potentiate venetoclax activity in non-Hodgkin lymphoma by targeting MCL-1 [abstract no. 880]. Cancer Res. 2018;78(13 Suppl). \n                    https:\/\/doi.org\/10.1158\/1538-7445.AM2018-880\n                    \n                  .","DOI":"10.1158\/1538-7445.AM2018-880"},{"issue":"Suppl 1","key":"1175_CR16","first-page":"1540","volume":"130","author":"A Tiwari","year":"2017","unstructured":"Tiwari A, Edani D, Ayello J, et al. Polatuzumab vedotin alone or in combination with obinutuzumab synergistically enhances in vitro cytotoxicity and cytokine release against CD20\u2009+\/CD79B\u2009+\u2009burkitt lymphoma (BL)\/primary mediastinal large B cell lymphoma (pmbl) [abstract]. Blood. 2017;130(Suppl 1):1540.","journal-title":"Blood"},{"issue":"S1","key":"1175_CR17","first-page":"S5","volume":"99","author":"D Lu","year":"2016","unstructured":"Lu D, Girish S, Marchand M, et al. Concentration-QTc analysis of polatuzumab vedotin in patients with B-cell hematologic malignancies [abstract no. PC-02]. Clin Pharmacol Ther. 2016;99(S1):S5.","journal-title":"Clin Pharmacol Ther."},{"issue":"23","key":"1175_CR18","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1182\/blood.V126.23.1525.1525","volume":"126","author":"D Lu","year":"2015","unstructured":"Lu D, Jin JY, Gibiansky L, et al. Exposure-response analysis to assist selection of dose and treatment duration for polatuzumab vedotin as a single agent or in combination with rituximab for the treatment of B-cell lymphoma [abstract]. Blood. 2015;126(23):1525.","journal-title":"Blood"},{"issue":"S1","key":"1175_CR19","first-page":"S71","volume":"105","author":"R Shi","year":"2019","unstructured":"Shi R, Lu T, Ding H, et al. Ethnicity sensitivity assessment of polatuzumab vedotin pharmacokinetics in relapsed-refractory non-hodgkin lymphoma [abstract no. PII-102]. Clin Pharmacol Ther. 2019;105(S1):S71.","journal-title":"Clin Pharmacol Ther."},{"issue":"S1","key":"1175_CR20","first-page":"S88","volume":"97","author":"D Lu","year":"2015","unstructured":"Lu D, Jin JY, Gibiansky L, et al. Population pharmacokinetics and exposure-response assessment of anti-CD79B antibody drug conjugate in patients: interim analysis results [abstract no. PII-095]. Clin Pharmacol Ther. 2015;97(S1):S88-9.","journal-title":"Clin Pharmacol Ther."},{"issue":"S1","key":"1175_CR21","first-page":"S71","volume":"105","author":"CS Shemesh","year":"2019","unstructured":"Shemesh CS, Agarwal P, Lee C, et al. Pharmacokinetics and drug interaction potential of polatuzumab vedotin in combination with R\/G-CHP in patients with B-cell non-hodgkin lymphoma [abstract no. PII-101]. Clin Pharmacol Ther. 2019;105(S1):S71","journal-title":"Clin Pharmacol Ther."},{"issue":"12","key":"1175_CR22","first-page":"e203","volume":"37","author":"P Agarwal","year":"2017","unstructured":"Agarwal P, Lu D, Samineni D, et al. Clinical pharmacokinetics (PK) of polatuzumab vedotin (Pola) in combination with rituximab (R), obinutuzumab (G), cyclophosphamide (C), doxorubicin (H) and bendamustine (B) in 1 L or relapsed\/refractory (R\/R) non-Hodgkin\u2019s lymphoma (NHL) patients [abstract no. 283]. Pharmacother. 2017;37(12):e203.","journal-title":"Pharmacother."},{"issue":"6","key":"1175_CR23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","volume":"16","author":"MC Palanca-Wessels","year":"2015","unstructured":"Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704\u201315.","journal-title":"Lancet Oncol."},{"issue":"5","key":"1175_CR24","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","volume":"6","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254\u201365.","journal-title":"Lancet Haematol."},{"issue":"22","key":"1175_CR25","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood.V128.22.622.622","volume":"128","author":"T Phillips","year":"2016","unstructured":"Phillips T, Brunvand M, Chen A, et al. Polatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-hodgkin lymphoma: preliminary safety and clinical activity of a phase Ib\/II study [abstract]. Blood. 2016;128(22):622.","journal-title":"Blood"},{"issue":"s2","key":"1175_CR26","first-page":"173","volume":"102","author":"M Matasar","year":"2017","unstructured":"Matasar M, Herrera AF, Kamdar M, et al. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed\/refractory follicular lymphoma or diffuse large B-cell lymphoma: updated results of a phase 1B\/2 study [abstract no. S468]. Haematologica. 2017;102(s2):173.","journal-title":"Haematologica."},{"issue":"Suppl 1","key":"1175_CR27","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1182\/blood-2018-99-118551","volume":"132","author":"LH Sehn","year":"2018","unstructured":"Sehn LH, Herrera AF, Matasar MJ, et al. Polatuzumab vedotin (POLA) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): updated results of a phase (PH) IB\/II study [abstract]. Blood. 2018;132(Suppl 1):1683.","journal-title":"Blood"},{"issue":"S1","key":"1175_CR28","first-page":"80","volume":"185","author":"A McMillan","year":"2019","unstructured":"McMillan A, Sehn L, Herrera A, et al. Updated results from a phase Ib\/II study in patients (pts) with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL) treated with polatuzumab vedotin (Pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) [abstract no. BSH19-PO-079]. Br J Haematol. 2019;185(S1):80.","journal-title":"Br J Haematol."},{"issue":"15_suppl","key":"1175_CR29","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1200\/JCO.2018.36.15_suppl.7507","volume":"36","author":"Laurie Helen Sehn","year":"2018","unstructured":"Sehn LH, Kamdar M, Herrera AF, et al. Randomized phase 2 trial of polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) in relapsed\/refractory (r\/r) FL and DLBCL [abstract no. 7507]. J Clin Oncol. 2018;36(15 Suppl).","journal-title":"Journal of Clinical Oncology"},{"issue":"S1","key":"1175_CR30","first-page":"348","volume":"2","author":"LH Sehn","year":"2018","unstructured":"Sehn LH, Kamdar M, Herrera AF, et al. Adding polatuzumab vedotin (POLA) to bendamustine and rituximab (BR) treatment improves survival in patients with relapsed\/refractory dlbcl: results of a phase 2 clinical trial [abstract no. S802]. HemaSphere. 2018;2(S1):348\u20139.","journal-title":"HemaSphere."},{"key":"1175_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30091-9","author":"H Tilly","year":"2019","unstructured":"Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(19)30091-9\n                    \n                  .","journal-title":"Lancet Oncol."},{"issue":"Suppl 1","key":"1175_CR32","first-page":"4120","volume":"130","author":"A Forero-Torres","year":"2017","unstructured":"Forero-Torres A, Kolibaba KS, Tilly H, et al. Polatuzumab vedotin combined with obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (G-CHP) for patients with previously untreated diffuse large b-cell lymphoma (DLBCL): updated results of a phase IB\/II study [abstract]. Blood. 2017;130(Suppl 1):4120.","journal-title":"Blood"},{"issue":"23","key":"1175_CR33","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1182\/blood.V126.23.2726.2726","volume":"126","author":"NL Bartlett","year":"2015","unstructured":"Bartlett NL, Chen AI, Kolibaba KS, et al. Polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for patients with previously untreated diffuse large b-cell lymphoma (DLBCL): preliminary results of a phase Ib dose-escalation. Blood. 2015;126(23):2726.","journal-title":"Blood"},{"issue":"s2","key":"1175_CR34","first-page":"4","volume":"102","author":"H Tilly","year":"2017","unstructured":"Tilly H, Sharman J, Bartlett N, et al. Pola-R-CHP: polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, prednisone for patients with previously untreated diffuse large B-cell lymphoma [abstract no. S106]. Haematologica. 2017;102(s2):4.","journal-title":"Haematologica."},{"issue":"22","key":"1175_CR35","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1182\/blood.V128.22.1853.1853","volume":"128","author":"H Tilly","year":"2016","unstructured":"Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL): updated results of a phase Ib\/II study [abstract]. Blood. 2016;128(22):1853.","journal-title":"Blood"},{"key":"1175_CR36","doi-asserted-by":"crossref","unstructured":"Diefenbach C, Kahl B, Banerjee L, et al. Polatuzumab vedotin (Pola)\u2009+\u2009obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed\/refractory (R\/R) follicular lymphoma (FL): interim analysis of a phase Ib\/II trial [abstract no. 7505]. J Clin Oncol. 2019;37(15 Suppl).","DOI":"10.1200\/JCO.2019.37.15_suppl.7505"},{"key":"1175_CR37","doi-asserted-by":"crossref","unstructured":"Hatake K, Kinoshita T, Terui Y, et al. A phase I pharmacokinetic and safety study of polatuzumab vedotin in Japanese patients with relapsed\/refractory B-cell non-Hodgkin lymphoma: a comparison with non-Japanese DCS4968\u00a0g study [abstract no. e19070]. J Clin Oncol. 2016;34(15 Suppl).","DOI":"10.1200\/JCO.2016.34.15_suppl.e19070"}],"updated-by":[{"DOI":"10.1007\/s40265-019-01214-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01175-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01175-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01175-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T16:22:50Z","timestamp":1600273370000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01175-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,27]]},"references-count":37,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01175-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,27]]},"assertion":[{"value":"27 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Polatuzumab Vedotin: First Global Approval, written by Emma D. Deeks, was originally published Online First without Open Access. After publication in volume 79, issue 13, pages 1467\u20131475 Roche\/GCC requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Roche\/GCC. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Polatuzumab Vedotin: First Global Approval, written by Emma D. Deeks, was originally published Online First without Open Access. After publication in volume 79, issue 13, pages 1467\ufffd\ufffd\ufffd1475 Roche\/GCC requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Roche\/GCC. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Polatuzumab Vedotin: First Global Approval, written by Emma D. Deeks, was originally published Online First without Open Access. After publication in volume 79, issue 13, pages 1467\ufffd\ufffd\ufffd1475 Roche\/GCC requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Roche\/GCC. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Emma Deeks is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}